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KETIDAKSTABILAN GENOMIK MIKROSATELIT MITOKONDRIA 
DAN MUTASI BRAFV600E DALAM TUMOR SISTEM SARAF PUSAT 
ABSTRAK 
 Tumor sistem saraf pusat dikenali sebagai salah satu kanser merbahaya dan 
boleh membawa maut di seluruh dunia. Himpunan pelbagai perubahan genetik dalam 
genom nuklear dan mitokondria dipercayai terlibat dalam pembentukan tumor otak. 
Ketidakstabilan mikrosatelit mitokondria (mtMSI) adalah satu perubahan pada jujukan 
berulang dalam genom mitokondria yang sering berlaku dalam beberapa kanser 
manusia. Sementara itu, BRAFV600E adalah onkogen nuklear yang bermutasi dan kerap 
dijumpai dalam pelbagai jenis kanser. Walau bagaimanapun, mutasi mtMSI dan 
BRAFV600E dalam kes tumor otak belum dilaporkan di Malaysia setakat ini. Oleh itu, 
kajian ini bertujuan untuk menentukan status/tahap mtMSI dan mutasi BRAFV600E 
dalam satu siri pesakit Melayu yang menghidapi tumor otak, seterusnya untuk 
mengenalpasti hubungan mereka dengan ciri-ciri klinikopatologi. Perubahan mtMSI 
dan mutasi BRAFV600E dianalisa dalam 50 sampel tumor otak bersama-sama sampel 
darah pesakit. Status mtMSI dianalisa menggunakan primer-primer mtMSI yang 
spesifik dan keputusannya dibandingkan dengan data ‘revised Cambridge Reference 
Sequences’ (rCRS). Bagi analisis mutasi BRAFV600E, ujian PCR-RLFP digunakan 
untuk mengenalpasti turutan variasi, diikuti dengan penjujukan langsung dan 
dibandingkan menggunakan BLAST dari pangkalan data NCBI. Keputusan 
menunjukkan lapan perubahan mtMSI dikesan pada D310 dan D16184 dari gelung 
anjakan (D-loop) (16%). Daripada jumlah ini, satu perubahan C5TC4> C8TC pada 
D16184 belum pernah dilaporkan dalam pangkalan data MITOMAP yang dikenal 
pasti dalam kajian ini. Tiada hubungan ditemui antara status mtMSI dan data 
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klinikopatologi. Selain itu, mutasi BRAFV600E telah dikesan dalam 11 daripada 50 
pesakit (22%). Bahkan juga, tiada kolerasi penting antara ciri klinikal dengan mutasi 
BRAFV600E yang diperhatikan dalam kajian ini. Seterusnya, kolerasi antara status 
mtMSI dan mutasi BRAFV600E juga dianalisa, namun, tiada hubungan penting 
dikenalpasti antara kedua-dua mutasi tersebut. Kajian ini memberi gambaran tentang 
ketidakstabilan genom mitokondria dan mutasi BRAF pesakit tumor otak. Oleh itu, 
analisa yang lebih terperinci melibatkan sejumlah besar pesakit diperlukan untuk 
menentukan peranan yang sebenar bagi kedua-dua perubahan genetik berkenaan di 




MITOCHONDRIAL MICROSATELLITE GENOMIC INSTABILITY 
AND BRAFV600E MUTATION IN CENTRAL NERVOUS SYSTEM TUMORS 
ABSTRACT 
 The central nervous system tumor is known as one of the fatal cancers 
worldwide. The accumulation of multiple genetic alterations of the nuclear and 
mitochondrial genome is believed to be engaged in brain tumorigenesis. Mitochondrial 
microsatellite instability (mtMSI) is a change in repetitive sequences of the 
mitochondrial genome, has been described as a high occurrence in several human 
cancers. Meanwhile, the BRAFV600E is the most prevalent mutated nuclear oncogene 
that has been identified in multiple malignancies. Nevertheless, mtMSI and 
BRAFV600E mutation in brain tumor cases have not been reported in Malaysia, so far. 
Therefore, this study aims to determine the mtMSI status and BRAFV600E mutation in 
a series of Malay patients with brain tumors and to evaluate their association with 
clinicopathological features. The mtMSI alterations and BRAFV600E mutations were 
examined in a total of 50 paired brain tumor tissues and blood samples.  The mtMSI 
status was analysed using mtMSI specific primers and the results were compared with 
the revised Cambridge References Sequences (rCRS). For the analysis of the 
BRAFV600E mutation, the PCR-RLFP assay was used for sequence variation, followed 
by direct sequencing and aligned using BLAST from the NCBI site.  The results 
revealed eight mtMSI alterations were detected in D310 and D16184 of the 
displacement loop (D-loop) region (16%). Of these, one alteration C5TC4>C8TC in the 
D16184 region has not been previously reported in the MITOMAP database identified 
in this study. No association was found between mtMSI status and clinicopathological 
data. Additionally, BRAFV600E mutation has been detected in 11 out of 50 patients 
xvi 
(22%). Similarly, no significant association between clinical features with BRAFV600E 
mutation observed in this study. The correlation between mtMSI status and BRAFV600E 
mutation also was analysed, however, no association identified between both 
alterations in all screened patients. This study provides insights into mitochondrial 
genome instability and BRAF mutation of brain tumor patients. A more detailed 
analysis involving a large number of patients is needed to establish the exact role of 







CHAPTER 1  
 
INTRODUCTION 
1.1 General Introduction 
Central nervous system tumors (CNS) are relatively common and potentially 
life-threatening which its incidence is increasing annually in the world. CNS tumors 
consist of more than 120 distinct types which cover 15% to 20% of all malignancies 
occurring in childhood and adolescence (Johnson et al., 2017). Besides, it became the 
second most common cancer in children (11.4%) after leukemia (46.8%) between 
2010 and 2012 in Malaysia (Rajagopal et al., 2017). 
Nonetheless, molecular characterization of brain tumor is not fully understood 
at present. Brain tumors, like other solid tumors, are likely to develop due to multiple 
genetic alterations, including the oncogenes activation and the inactivation of 
functional tumor suppressor genes (Crespo et al., 2015; Mohamed Yusoff et al., 2015). 
The comprehension of genomic instability in tumorigenesis could provide a deeper 
level of understanding cancer as it is believed to contribute to the initiation and 
progression of tumors. 
Microsatellite instability (MSI) is one of the major expressions of genomic 
instability. Most studies have determined the roles of nuclear MSI in many types of 
cancer, which are thought to have resulted from a defect during the replication process 
(Janavicius et al., 2010; Shokal and Sharma, 2012; Yamamoto and Imai, 2015). 
However, mitochondrial microsatellite instability (mtMSI) which is also considered as 
a subject to genetic alterations in cancer, is lacking in the understanding of its role in 
cancer progression. Studies in this field were relatively few, particularly in brain 
tumors (Kirches et al., 2001; Yeung et al., 2014). Therefore, the findings of this study 
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could provide a large quantity of data for future research whilst mtMSI could be 
developed as a useful molecular marker in clinical settings. 
Apart from that, the activation of oncogenic mutations has been suggested in 
their role in brain neoplasms. Almost 80% of all genetic variations correlate to the hot 
spot T1799A trans-version which induces V600E mutation, consequently converts 
BRAF into oncogenic kinases (Wan et al., 2004; Cho et al., 2014). BRAFV600E 
mutation has been identified in several types of cancers including melanoma, thyroid 
and colorectal cancers (Tran et al., 2011; Hong et al., 2014; Maxwell et al., 2017). 
Recently, this oncogenic mutation was highly reported in a wide spectrum of brain 
tumors (Usubalieva et al., 2015; Behling et al., 2016; Bufalo et al., 2018). However, 
current targeted therapies in brain tumors are still exhausted, hence the understanding 
of molecular mechanisms based on the genesis and progression of this tumor is 
essential. 
Identification of the molecular mechanisms involved in brain tumors formation 
with respect to the oncogenes encoded by the nuclear genome and defect in the 
mitochondrial genome is anticipated in the diagnosis of brain tumors. Thus, a better 
understanding of these molecular mechanisms is crucial to regulate more effective 
treatment protocols regarding brain tumor development. 
1.2 Rationale of Study 
Over the past few years, researches on mitochondrial alterations have been found 
to contribute in cancer development. Nevertheless, the current research on the analysis 
of microsatellite instability in the mitochondrial genome is still scarce compared to the 
nuclear genome. The instabilities of the mitochondrial genome in tumorigenesis need 
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to be understood clearly, as it could be developed as a reliable molecular marker for 
cancer development and have the potential for tracking tumor progression. Currently, 
MSI has been recognised as a useful screening tool for the identification of colorectal 
cancer. Therefore, the findings of this study were hoped to provide a large quantity of 
data of mtMSI in brain tumors for future research in order to provide a novel 
approaches and target in the development of anti-cancer therapeutics for brain tumors.  
The development of more selective targeted therapies for BRAFV600E mutation and 
the design of future clinical trials for primary brain tumors is dependent on the 
understanding of the molecular genetic lesion that drives its pathogenesis. However, 
targeting BRAFV600E mutation has been proven to be beneficial for some cancers, but 
there are still restricted numbers of high-level evidence of the efficacy in primary brain 
tumors among Malay patients. Thus, this study may provide a better understanding of 
BRAFV600E mutation related to the pathogenesis of primary brain tumors that could be 
developed as a molecular indicator which can be used in clinical settings.  
1.3 Hypotheses of the Study 
 In this study, it is hypothesized that: 
i. There are occurrences of mtMSI and BRAFV600E mutation in brain tumor 
patients. 
ii. There is an association between clinical parameters and mtMSI in brain tumor 
patients. 
iii. There is an association between clinical parameters and BRAFV600E mutation 
in brain tumor patients. 
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1.4 Research Objectives 
1.4.1 General objectives 
 
 The main aim of this study was to explore the instability changes of 
mitochondrial genome as well as the alteration of BRAF gene that might explain the 
aggressive nature of brain tumors.  
1.4.2 Specific objectives 
i. To evaluate the status of mitochondrial genome microsatellite instability 
(mtMSI) in patients with brain tumors 
ii. To identify the prevalence of BRAFV600E mutation in brain tumor samples. 
iii. To analyse the association between mtMSI and BRAFV600E with clinical 
findings of brain tumors in Malay patients.  
iv. To assess the association between mtMSI and BRAFV600E mutation in brain 
tumor samples. 
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CHAPTER 2  
 
LITERATURE REVIEW 
2.1 Central Nervous System Tumors 
2.1.1 Classification of Brain Tumors 
The central nervous system (CNS) tumor is referred to as neoplasm originating 
from the intracranial tissues and meninges caused by abnormal growth (McKinney, 
2004). These tumors grow in the areas of the brain, spinal cord and meninges, but brain 
tumors are known as the largest group. CNS tumors could be fatal as even the benign 
(non-cancerous) tumor tends to transform into malignant (cancerous) tumors 
dependent on its location (Goh et al., 2014).   
Brain tumors are classified based on World Health Organization (WHO) 
classification which was first published in the year 2000 assigning grade I to IV 
(Kleihues et al., 2002). This system is based on the similarity of the tumor cells to 
normal cells, tumor growth rate, the appearance of necrotic cells in the center of the 
tumor and the presence of definitive tumor margins as well as vascularity. Grade I and 
II are considered as slow-growing tumor (benign). Meanwhile, Grade III and IV are 
rapid-growing tumor (malignant) and actively invading adjacent tissue (Hill et al., 
2002). Additionally, WHO classifications have been updated in 2007 (Louis et al., 
2007). Classification regarding the distinct histology and clinical behavior is 
significant for specific clinical presentations, treatment and outcomes for each tumor 
subtypes (Ostrom et al., 2015).  
Based on the comprehensive studies over the past two decades, clarification of 
the genetic principle of tumorigenesis in the common and several rarer types of brain 
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tumors create the prospect that may contribute to the brain tumor classification. 
Therefore, the WHO classification of CNS tumors system has formulated an approach 
of how the diagnoses of CNS tumor in the molecular stage should be structured. This 
classification is based on the molecular and histology parameters in many tumor 
entities (Louis et al., 2016). The classification of CNS tumors according to WHO is 





Table 2.1 The 2016 WHO Classification of CNS tumors (adapted from Louis et 
al., 2016) 
Types of tumors Grade 
Diffuse astrocytic and oligodendroglial tumors  
Diffuse astrocytoma, IDH-mutant II 
Gemistocytic astrocytoma, IDH-mutant II 
Anaplastic astrocytoma, IDH-mutant III 
Glioblastoma, IDH-wildtype IV 
Glioblastoma, IDH-mutant IV 
Glioblastoma, NOS IV 
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted II 
Oligoastrocytoma, NOS III 
Other astrocytic tumors  
Pilocytic astrocytoma I 
Subependymal giant cell astrocytoma I 
Pleormorphic xanthoastrocytoma II 
Ependymal tumors  
Subependymoma  I 
Myxopapillary ependymoma I 
Ependymoma  II 
Ependymoma, RELA fusion-positive II or III 
Anaplastic ependymoma  III 
Neuronal and mixed neuronal-glial tumors  
Dysembryoplastic neuroepithelial tumor I 
Gangliocytoma  I 
Ganglioglioma  I 
Anaplastic ganglioglioma  III 
Embryonal tumors  
Medulloblastomas (all subtypes) IV 
Embryonal tumor with multilayered rosettes, C19MC-altered IV 
Medulloepithelioma  IV 
Atypical teratoid/rhabdoid tumor IV 
Tumors of the cranial and paraspinal nerves  
Schwannoma  I 
Neurofibroma  I 
Perineurioma  I 
Malignant peripheral nerve sheath tumor  II, III or 
IV 
Meningiomas  
Meningioma  I 
Atypical meningioma  II 
Anaplastic (malignant) meningioma  III 
Tumors of the sellar region  
Craniopharyngioma  I 
Granular cell tumor of the sellar region  I 
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2.1.2 Epidemiology of Brain Tumors 
Generally, the incidence of brain tumors is higher in the West countries 
compared to the East countries and most common in developed countries than in 
developing countries (Kalan-Farmanfarma et al., 2019). According to the Global 
Burden of Disease Study in 2016, the incidence of brain tumors was 330 000 cases and 
the deaths were 227 000 cases which occurred worldwide. The most top three countries 
that contribute to this number of cases were China, the United States, and India.   
Brain and other CNS tumors are the tenth causes of cancer-related deaths in the 
United States (CBTRUS, 2018). According to CBTRUS 2018 report, it was estimated 
that 26,170 new cases of primary brain tumors were predicted to be diagnosed in the 
United States in the year of 2019 (CBTRUS, 2018). Nonetheless, the incidence of brain 
tumors from 2008-2012 was 356,858 cases including 117,023 of malignant and 
239,835 of non-malignant tumors (Ostrom et al., 2015). Overall, the most frequently 
reported histology of brain tumors is meningioma, followed by tumors of the pituitary 
and glioblastoma (Ostrom et al., 2015). Besides, statistics had shown that the 
incidences of these particular tumors were diagnosed to be higher in males (139,608 
cases) than in females (116,605 cases) in 2012 (Patel et al., 2019). The distribution of 
all primary CNS tumors from 2008-2012 in the United States shown in Figure 2.1.   
In the United Kingdom, nearly 9000 patients are diagnosed with primary brain 
tumors each year. Furthermore, over 102,000 people are living with primary brain 
tumors, with only 14% of patients with primary brain tumors are alive after 10 years 
after diagnosis (Kurian et al., 2018). In Japan, the second major cause of deaths caused 
by malignant tumors at the age of 0-14 years was brain tumors. Nevertheless, brain 
tumors were the main factor in 2011 as the fatality rate of pediatric brain tumors 
9 
increased. Additionally, there were 84 deaths reported among children aged 0-14 years 
with brain tumors in 2013 (Nishi, 2014).   
Among 2,589,448 populations in five cities in China, 636 people have been 
diagnosed with primary brain tumors which were found to be 31.16% of malignant 
and 68.94% of benign tumors between 2005 and 2006. The prevalence rate of primary 
brain tumors is higher in female compared to the male population. Additionally, 
glioma appeared to be common in the youngest age (0-19 years) while pituitary 
adenomas and glioma frequently occurred in patients age from 20 to 59 years (Jiang 
et al., 2011). However, the number of cases diagnosed in China increased between 
96,980 to 119,885 cases in 2016 (Patel et al., 2019). 
The prevalence of primary malignant brain tumors in East India occurred for 
both males and females with ratio of 2.3:1 and at the age of 20-60 years. The most 
common broad histological type is astrocytic tumors. Overall, the frequency of 
primary malignant brain tumors in East India cover up to 1% of all malignancies which 
involve mostly young and middle-age patients (Krishnatreya et al., 2014). 
The incidence of brain tumors covers approximately 1.95% of all malignancies 
in Malaysia which shown an increasing trend every year among adults and children 
(Goh et al., 2014). Back in the year of 2016, it was detected that 598 incidence and 
nearly 431 deaths occurred in Malaysia (Patel et al., 2019). In Sarawak, it was 
calculated that the crude rate of brain tumors was 4.6 per 100,000 population between 
2009 to 2012. The most common brain tumor was meningioma (32.3%) followed by 
astrocytoma (19.4%) (Goh et al., 2014). A cohort population-based study in the east 
coast of Malaysia revealed that the most prevalent primary brain tumor occurred in 
adult was meningioma tumor (32.7%) followed by glioblastoma (7.8%) (Md Dzali et 
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Figure 2.1 Distribution of primary brain and CNS Tumors by CBTRUS 
Histology Groupings and Histology according to CBTRUS Statistical Report: NPCR 
and SEER, 2008-2012. This figure adapted from (Patel et al., 2019).   
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2.2 Mitochondria and Tumorigenesis 
2.2.1 Mitochondria  
Mitochondria are ubiquitous intracellular organelles which can be found in 
most eukaryotic organisms that accounted for 25% of the cytoplasm volume. It has a 
variable length with a transverse diameter of 0.1 to 0.5 µM (Mohamed Yusoff et al., 
2015).  This organelle has an oblong or ovoid shape and its unique characteristics can 
be seen by electron microscopy (Medeiros, 2008). Generally, mitochondria have four 
compartments which are the outer membrane, inner membrane, intermediate space and 
matrix (Mohamed Yusoff et al., 2015).  
The mitochondrial outer and inner membranes consist of a phospholipid bilayer 
and proteins. The outer membrane is highly permeable which allowing molecules 
<10,000 Da to diffuse through a special protein channel referred to as mitochondrial 
porin or voltage-dependent anion-selective channel (VDAC) (De Pinto and Palmieri, 
1992; Mannella et al., 1992). In contrast, the inner membrane is impermeable to most 
ions and molecules. This membrane is essential in synthesis of ATP and electron 
transport chain. Enzymes, proteins, and peptides including chaperones, DNA 
polymerase, ribosomes, mtDNA, mRNAs, and tRNAs are located in the mitochondrial 
matrix (Mohamed Yusoff et al., 2015). 
2.2.2 Mitochondrial Function 
Mitochondria are best known as the powerhouse of cellular energy in the adenosine 
triphosphate (ATP) form via oxidative phosphorylation (OXPHOS) system (Lu et al., 
2009). This ATP production is done by using the energy produced during the electron 
transport chain and occurs through chemiosmosis. OXPHOS system is carried out by 
five multi-subunit protein complexes which are embedded in the inner membrane of 
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mitochondria (Shen et al., 2010). Complex I – IV are involved in transferring electrons 
and oxygen molecules act as the final electron acceptor. By transferring the electron 
from one electron acceptor to another, some energy is released and is used in 
chemiosmosis to produce ATP from ADP and inorganic phosphate which catalysed by 
Complex V (ATP synthase). 
Apart from that, mitochondria are a known contributor for reactive oxygen 
species (ROS) generation, metabolic homeostasis and responsible for initiation and 
execution of apoptosis (Turnbull et al., 2010; Indran et al., 2011; Sullivan and Chandel, 
2014). Moreover, mitochondria also serve as a platform for producing biosynthesis 
building blocks (Zong et al., 2016). Thus, roles of mitochondria are critical in several 
cellular processes that are significant for cell metabolism, growth, and survival. 
2.2.3 Human Mitochondrial Genome 
Mitochondria contain their own genome with all the fundamental machinery 
needed for their expression (Schon et al., 2012). Human mitochondrial DNA (mtDNA) 
is maternally inherited and was first discovered in 1963 (Nass and Nass, 2004; Schon 
et al., 2012). The first sequence of the mitochondrial genome was available in 1981 
and was subsequently revised in 1999 (Anderson et al., 1981; Andrews et al., 1999). 
mtDNA was presented in the form of close-double stranded circular DNA of 16,569 
nucleotide pairs (Taanman, 1999).  
The organization of human mtDNA is extremely compact with genes and some 
of the genes are overlapped as shown in Figure 2.2 (Mohamed Yusoff et al., 2015).  
The non-coding region is the control region of mtDNA including the displacement 
loop (D-loop) region that occupied 1122 bp in the mitochondrial genome (Clayton, 
2000). Hypervariable 1 (HV1), hypervariable 2 (HV2) and hypervariable 3 (HV3) that 
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are rich in polymorphisms are also located in the control region (Tsutsumi et al., 2006). 
There are two distinct strands of mtDNA namely as a heavy strand (H-strand) and light 
strand (L-strand) according to their buoyant density in alkaline caesium chloride 
gradient (Montoya et al., 1982). D-loop region contains the origin for the replication 
of H-strand synthesis and two promoters for the transcription process. mtDNA consists 
of 37 genes coding for 2 rRNAs, 22 tRNAs and 13 polypeptides which are responsible 
for the OXPHOS system (Schon et al., 2012). The H-strand is rich in cytosine, consists 
of 2 rRNAs, 14 tRNAs, and 12 polypeptides whilst the L-strand is rich in guanine and 
composed of 8 tRNAs and only one polypeptide (Mohamed Yusoff et al., 2015).   
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Figure 2.2 The human mitochondrial genome 
 
Abbreviation: Y, Tyrosine; S, Serine; D, Aspartic acid; K, Lysine; G, Glycine; R, 
Arginine; H, Histidine; E, Glutamic acid; T, Threonine; P, Proline. The displacement 
loop (D-loop), or non-coding control region contains the promoters for transcription 
of the L (LSP) and H strands (HSP1 and HS2) and the origin of replication of the H 
strand (OH). OL, the origin of light-strand replication. This figure was adapted from 
(Mohamed Yusoff et al., 2015).   
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2.2.4 Alteration of Mitochondrial Functions and Tumorigenesis 
Normal differentiated cells produce energy via the OXPHOS system that is 
essential for cellular processes (Hsu et al., 2016). Nonetheless, most cancer cells 
produce energy through glycolysis even in the existence of oxygen, termed as ‘aerobic 
glycolysis’. This phenomenon has been observed by Otto Warburg in 1926 which 
encouraged him to propose that the alteration in mitochondrial respiration are the 
fundamental basis for aerobic glycolysis and tumor (Koppenol et al., 2011; Otto, 
2016). Hence, researchers have begun to investigate the mitochondrial alterations in 
numerous cancers afterward. The previous study demonstrated that the restriction of 
the OXPHOS function through the cancer cells incubation with oligomycin led to a 
rapid increase of aerobic glycolysis, indicating that the impairment of mitochondrial 
bioenergetic function caused the tumor cells to become glycolytic (López-Armada et 
al., 2013). Due to this evidence, tumor cells have upregulated glycolysis as an 
adaptational mechanism to support their biosynthetic requirements rather than the 
mitochondrial respiratory system, suggesting the partial defect in mitochondria (Lu et 
al., 2009).  
Reactive oxygen species (ROS) such as peroxide, superoxide, and hydrogen 
peroxide are the natural by-product of the mitochondrial respiratory chain when some 
of the transferring electrons are instead leaked out of the chain (Lu et al., 2009). Lower 
production of ROS is crucial in regulating cellular signaling, proliferation of normal 
cells, host defense and gene expression (Sullivan and Chandel, 2014; Nita and 
Grzybowski, 2016). Nevertheless, the uncontrolled ROS generation is capable of 
damaging cellular components including the DNA, proteins, and lipids, consequently 
caused the dysfunction of the cell (Lu et al., 2009; Sullivan and Chandel, 2014). 
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Furthermore, elevated levels of ROS production have long been recognised as a 
hallmark in many tumors and cancer cell lines (Szatrowski and Nathan, 1991). Based 
on the observation by Pelicano et al. (2009), the perturbation of the mitochondrial 
respiratory chain generates subclones of cells with an increase of ROS, active 
proliferation, increased cellular motility and invasive behaviours in vivo and in vitro 
of breast cancer cells. Therefore, it is suggested that stimulation of ROS is believed to 
contributes to genomic instability promoting tumorigenesis.  
In addition, ROS can also lead to the degradation of the mitochondrial genome 
(Harman, 1988; Singh, 2006). This is due to the continuous exposure of ROS may 
induce oxidative stress which could lead to mtDNA alterations as the location of 
mtDNA is near the ROS production site (Figure 2.3). Particularly, mtDNA has a lack 
of introns and protective histones besides possessing a defective DNA repair system 
(Zong et al., 2016). Due to these reasons, mtDNA is susceptible to the high rate of 






Figure 2.3 Mitochondrial superoxide (O2•−) production by electron transport 
chain (ETC) 
 
The elevated levels of O2•− induce damage to macromolecules, including lipids, 
proteins, and nucleic acids, and promote mitochondrial dysfunction. Absence of 
histones in mitochondrial DNA (mtDNA) and limited DNA repair mechanisms make 
mitochondria highly susceptible to DNA damage induced by O2•−.  
Abbreviation: ADP, Adenoxine diphosphate; ATP, Adenosine triphosphate; GPX, 
Glutathione peroxidase; H2O2, Hydrogen peroxide; IMM, Inner mitochondrial 
membrane; IMS, Intermembrane space. This figure was adapted from (Burgos-Morón 









2.2.5 Mitochondrial DNA Mutations in Cancer 
Notably, many solid tumors exhibit multiple alterations in the nuclear genome, 
but in recent years, researchers have now focused on the basis of mitochondrial DNA 
mutations because of its high frequency and wide distribution in carcinogenesis (Lee 
et al., 2010; Cormio et al., 2015)l. Previously, Larman and colleagues (2012) analysed 
226 patients with five different cancer types; acute myeloid leukemia, glioblastoma, 
ovarian, colon, and rectal adenocarcinoma. From the findings, they found that the 
prevalence of somatic mtDNA mutations occur at 13% to 63% across the five cancer 
types, suggesting that mtDNA mutations as a standard mechanism for damaging 
metabolic pathways in tumorigenesis (Larman et al., 2012). Although the role and 
mechanism of mtDNA mutations in cancer progression is still controversial and 
unclear, there is still a possibility that mitochondria could be a potential biomarker in 
tumorigenesis (Parr et al., 2006; Cruz-Bermúdez et al., 2017).  
Thus far, mitochondrial dysfunction caused by mtDNA mutations has been 
widely described in various cancer types such as lung, brain, thyroid, breast and 
colorectal cancers (Tong et al., 2003; Ma et al., 2010; Chen, 2012; Dai et al., 2013; 
Mohamed Yusoff, 2015; Gao et al., 2016). Despite that, studies of molecular alteration 
in the mitochondrial genome, for examples, large-scale deletions, point mutations, 
copy number changes, insertions, and microsatellite instability render a better 
understanding of mitochondrial dysfunction and tumorigenesis (Dai et al., 2013; 
Tipirisetti et al., 2013; Mohamed Yusoff et al., 2019). Over 30 mutations and 
sequential variations can be found in the mtDNA database; Mitomap 
(http://www.mitomap.org). These findings altogether indicate that mtDNA alterations 
have become a target in cancer research.   
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2.2.6 Mitochondrial Microsatellite Instability and Tumorigenesis 
Microsatellites are short tandem repeats of DNA sequences ranging from one 
to six in length (Kelkar et al., 2010). These repeats are scattered throughout the genome 
in various length from one individual to another due to the variable number of tandem 
repeats at each locus. However, the alterations in these elements are defined as 
microsatellite instability (MSI) which occurs due to insertions or deletions (indels) 
during DNA replication and the inefficiency of the DNA mismatch repair system to 
amend these errors (Ashtiani et al., 2013; Geurts-Giele et al., 2015). MSI was first 
reported in the nuclear genome of patients with colorectal cancer and later discovered 
in other cancers (Thibodeau et al., 1993; Viana-Pereira et al., 2011; Lee, Lee, Kim & 
Hwang et al., 2015; Shahsiah et al., 2017). Nevertheless, the role of MSI in the 
mitochondrial genome (mtMSI) which also believes may contribute to carcinogenesis, 
is still scarce and insufficiently characterized. 
An increase of mitochondrial instability has been found in various tumor types, 
hence, this event is considered as a key molecular step of mutations in cancer 
progression. The previous study by Kim et al. (2006) had identified the high frequency 
of mtMSI in colorectal cancer stroma among Korean patients. Another research based 
on primary and metastatic colorectal cancer tissues also reported that the mtMSI is 
shown to be greater in lymph node metastases compared to the primary tumor and 
distant metastases (Kleist et al., 2017).    
In addition, the prevalence of mtMSI was previously reported to be ranging 
from 10.2% to 62% of gastric cancer patients (Lee and Kim, 2014). A report was done 
by Pavicic and colleagues (2009) also pointed out that mtMSI event had occurred in 
breast cancer tissues which showed the allele changes (CA) in 24 out of 94 cases.  
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In 2005, Wang and team examined the occurrence of mtMSI in different types 
of female cancers (cervical, endometrial, ovarian and breast) and a follow up study 
was done in 2006 (Wang et al., 2005, 2006). Based on their findings, mtMSI event has 
been proposed as a potential marker in cancer progression.  
In brain tumor cases, only a few studies examined the occurrences of mtMSI 
alterations. The first study was conducted by Kirches et al. (1999) when they found a 
high frequency of mtDNA sequence variants in 12 astrocytic brain tumors. Two years 
later, they also reported a high prevalence of mtMSI in glioblastoma samples (15 out 
of 17) using laser microdissection and PCR technique (Kirches et al., 2001). In 2004, 
Vega and colleagues observed the instability in 27 (39.1%) of primary CNS tumors 
compared to the corresponding blood samples. Thus, it is proposed that mtMSI 




2.3 BRAF Gene 
2.3.1 BRAF and MAPK/ERK Pathway 
Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated 
kinase (ERK) pathway has emerged as a critical route for the regulation of inter- and 
intra-cellular communication including cell proliferation, differentiation, and survival 
(Cantwell-dorris et al., 2011). Specifically, the most dominant activator in 
MAPK/ERK signaling cascade is the v-RAF murine sarcoma viral oncogenes homolog 
B1 (BRAF) gene (Cantwell-dorris et al., 2011).  
BRAF is one of the RAF family which encodes a serine/threonine-protein 
kinase and possessed the highest basal kinase (Behling et al., 2016). This gene located 
on chromosome 7 (7q34) consists of 18 exons. BRAF acts as a signal mediator in this 
pathway from the extracellular environment to the nucleus (Myung et al., 2012). The 
extracellular signals, for instance, cytokines, hormones, and other growth factors bind 
with their receptors, results in the activation of the RAS G-protein. This results in 
dimerized BRAF, subsequently activates MEK which, in turn, activates ERK and 
consequently activates downstream transcription factors to stimulate various 
biochemical processes (Cantwell-dorris et al., 2011). 
The regulation of MAPK/ERK pathway is significant for homeostasis 
maintenance in response to extracellular signaling. It has been proposed that the 
hyperactivation of this pathway leads to cell-cycle arrest whereas aberrant signaling of 
the pathway may contribute to tumorigenesis (Davies et al., 2002). Also, alteration of 
MAPK/ERK pathway has been reported in ~30% of human cancers and previous data 
has revealed that BRAF mutation was found in 7% of cancers (Davies et al., 2002; 
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Garnett and Marais, 2004). Therefore, BRAF mutation has been identified as one of 
the important oncogenes involved in the alteration of MAPK/ERK pathway.   
2.3.2 BRAFV600E Mutation and Tumorigenesis 
In recent years, considerable efforts have been devoted to investigating the 
alterations of BRAF gene in various human cancers since the first investigation by 
Davies et al. (2002). They found that the high prevalence of BRAF mutation was 
frequent in many tumors (Davies et al., 2002). Since then, many researchers focused 
on the significance of BRAF alteration in cancer development and progression. The 
most common alteration observed in this oncogene is BRAFV600E mutation which 
substitutes the thymine to adenine at position 1799 of the gene (T1799A), 
subsequently, change of GTG to GAG at codon 600. This results in the exchange of 
the amino acid of valine to glutamic acid at position 600 (V600E) (Inumaru et al., 
2014). Of this, BRAFV600E protein constitutively activates the serine/threonine tyrosine 
kinase and its downstream protein kinase signaling cascade consequently induce 
oncogenesis (Figure 2.4) (Cantwell-Dorris et al., 2011).  
BRAFV600E mutation has been identified in several types of human cancers 
including melanoma, thyroid, colorectal, and brain (Davies et al., 2002; Tran et al., 
2011; Myung et al., 2012; Hong et al., 2014). This oncogenic mutation is a well-
characterized target in human melanoma, which has been detected up to 66% of 
primary cases (Davies et al., 2002). In 2014, Hong et al. (2014) reported an increase 
in BRAF-associated papillary thyroid cancers patients from 62.2% to 73.7% in the past 
two decades in Korea.  
Moreover, researchers have extensively examined the occurrences of 
BRAFV600E mutation in brain neoplasms (Dougherty et al., 2010; Schindler et al., 2011; 
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Donson et al., 2014; Kieran, 2014; Behling et al., 2016; Schreck et al., 2018). 
According to Myung et al. (2012), BRAFV600E mutation was identified in 36 cases of 
CNS tumors including pleomorphic xanthoastrocytoma, gangliogliomas, pilocytic 
astrocytomas, malignant tumors, anaplastic astrocytomas, glioblastomas, and 
oligodendrogliomas. In epitheloid glioblastomas, the BRAFV600E mutation was found 
in 50% of the cases (Kleinschmidt-DeMasters et al., 2013).  
Nevertheless, BRAFV600E was frequently detected in pediatric brain tumors 
compared to adults. This mutation is less common in adult gliomas with only 1-2% in 
glioblastomas and 2-5% in low-grade gliomas (Behling and Schittenhelm, 2019). 
Recently, a high frequency of BRAFV600E has been investigated in pediatric brain 
tumors including gangliogliomas, low-grade gliomas, epitheloid glioblastomas 
(Dougherty et al., 2010; Kleinschmidt-DeMasters et al., 2013; Donson et al., 2014). 
Donson et al. (2014) determined the high percentage of BRAFV600E mutation in 
pediatric gangliogliomas which occurred in five of 13 (38%) of the cases. 
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Figure 2.4 Oncogenic BRAF signaling pathway, A: MAPK/ERK pathway,  
B: Oncogenic BRAFV600E signaling 
Abbreviation: RTK, receptor tyrosine kinase
